| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CLINICAL STUDY |
1 Centre for Diabetes and Endocrinology, Barnsley NHS Foundation Trust Hospital, Gawber Road, Barnsley S75 2EP, UK and 2 Department of Cardiology, Royal Hallamshire Hospital, Sheffield, UK and 3 Academic Unit of Endocrinology, Division of Genomic Medicine, University of Sheffield, UK
(Correspondence should be addressed to T H Jones; Email: hugh.jones{at}bdgh-tr.trent.nhs.uk)
Objective: Low levels of testosterone in men have been shown to be associated with type 2 diabetes, visceral adiposity, dyslipidaemia and metabolic syndrome. We investigated the effect of testosterone treatment on insulin resistance and glycaemic control in hypogonadal men with type 2 diabetes.
Design: This was a double-blind placebo-controlled crossover study in 24 hypogonadal men (10 treated with insulin) over the age of 30 years with type 2 diabetes.
Methods: Patients were treated with i.m. testosterone 200 mg every 2 weeks or placebo for 3 months in random order, followed by a washout period of 1 month before the alternate treatment phase. The primary outcomes were changes in fasting insulin sensitivity (as measured by homeostatic model index (HOMA) in those not on insulin), fasting blood glucose and glycated haemoglobin. The secondary outcomes were changes in body composition, fasting lipids and blood pressure. Statistical analysis was performed on the delta values, with the treatment effect of placebo compared against the treatment effect of testosterone.
Results: Testosterone therapy reduced the HOMA index (–1.73 ± 0.67, P = 0.02, n = 14), indicating an improved fasting insulin sensitivity. Glycated haemoglobin was also reduced (–0.37 ± 0.17%, P = 0.03), as was the fasting blood glucose (–1.58 ± 0.68 mmol/l, P = 0.03). Testosterone treatment resulted in a reduction in visceral adiposity as assessed by waist circumference (–1.63 ± 0.71 cm, P = 0.03) and waist/hip ratio (–0.03 ± 0.01, P = 0.01). Total cholesterol decreased with testosterone therapy (–0.4 ± 0.17 mmol/l, P = 0.03) but no effect on blood pressure was observed.
Conclusions: Testosterone replacement therapy reduces insulin resistance and improves glycaemic control in hypogonadal men with type 2 diabetes. Improvements in glycaemic control, insulin resistance, cholesterol and visceral adiposity together represent an overall reduction in cardiovascular risk.
This article has been cited by other articles:
|
|
 |
|
  C. Vuong, S. H. M. Van Uum, L. E. O'Dell, K. Lutfy, and T. C. Friedman The Effects of Opioids and Opioid Analogs on Animal and Human Endocrine Systems Endocr. Rev., February 1, 2010; 31(1): 98 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Ermetici, F Donadio, L Iorio, A E Malavazos, A Dolci, E Peverelli, A M Barbieri, L Morricone, I Chiodini, M Arosio, et al. Peripheral insulin-like factor 3 concentrations are reduced in men with type 2 diabetes mellitus: effect of glycemic control and visceral adiposity on Leydig cell function Eur. J. Endocrinol., December 1, 2009; 161(6): 853 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Heufelder, F. Saad, M. C. Bunck, and L. Gooren Fifty-two-Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma Testosterone J Androl, November 1, 2009; 30(6): 726 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B Yeap, S A P. Chubb, Z. Hyde, K. Jamrozik, G. J Hankey, L. Flicker, and P. E Norman Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study Eur. J. Endocrinol., October 1, 2009; 161(4): 591 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aversa, R. Bruzziches, D. Francomano, M. Natali, and A. Lenzi Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? Therapeutic Advances in Urology, October 1, 2009; 1(4): 179 - 197. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Munzer, S. M. Harman, J. D. Sorkin, and M. R. Blackman Growth Hormone and Sex Steroid Effects on Serum Glucose, Insulin, and Lipid Concentrations in Healthy Older Women and Men J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3833 - 3841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. I Hackett Review: Androgens, erectile dysfunction and cardiovascular risk in type 2 diabetes The British Journal of Diabetes & Vascular Disease, September 1, 2009; 9(5): 214 - 217. [Abstract] [PDF]
|
|
|
|
|
|
G. I Hackett, N. S Cole, A. A Deshpande, M. D Popple, D. Kennedy, and P. Wilkinson Biochemical hypogonadism in men with type 2 diabetes in primary care practice The British Journal of Diabetes & Vascular Disease, September 1, 2009; 9(5): 226 - 231. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Caminiti, M. Volterrani, F. Iellamo, G. Marazzi, R. Massaro, M. Miceli, C. Mammi, M. Piepoli, M. Fini, and G. M.C. Rosano Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol., September 1, 2009; 54(10): 919 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Traish, F. Saad, R. J. Feeley, and A. Guay The Dark Side of Testosterone Deficiency: III. Cardiovascular Disease J Androl, September 1, 2009; 30(5): 477 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Meacham, C. A. Sklar, S. Li, Q. Liu, N. Gimpel, Y. Yasui, J. A. Whitton, M. Stovall, L. L. Robison, and K. C. Oeffinger Diabetes Mellitus in Long-term Survivors of Childhood Cancer: Increased Risk Associated With Radiation Therapy: A Report for the Childhood Cancer Survivor Study Arch Intern Med, August 10, 2009; 169(15): 1381 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Guay The Emerging Link Between Hypogonadism and Metabolic Syndrome J Androl, July 1, 2009; 30(4): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Theodoraki and P.-M. Bouloux Testosterone therapy in men Menopause Int, June 1, 2009; 15(2): 87 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Stanworth, D. Kapoor, K. S. Channer, and T. H. Jones Statin Therapy Is Associated With Lower Total but Not Bioavailable or Free Testosterone in Men With Type 2 Diabetes Diabetes Care, April 1, 2009; 32(4): 541 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wang, E. Nieschlag, R. Swerdloff, H. M. Behre, W. J. Hellstrom, L. J. Gooren, J. M. Kaufman, J.-J. Legros, B. Lunenfeld, A. Morales, et al. Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations J Androl, January 1, 2009; 30(1): 1 - 9. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Traish, A. Guay, R. Feeley, and F. Saad The Dark Side of Testosterone Deficiency: I. Metabolic Syndrome and Erectile Dysfunction J Androl, January 1, 2009; 30(1): 10 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Traish, F. Saad, and A. Guay The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance J Androl, January 1, 2009; 30(1): 23 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Misra, D. K Katzman, J. Cord, S. J Manning, D. Mickley, D. B Herzog, K. K Miller, and A. Klibanski Percentage extremity fat, but not percentage trunk fat, is lower in adolescent boys with anorexia nervosa than in healthy adolescents Am. J. Clinical Nutrition, December 1, 2008; 88(6): 1478 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R D Stanworth, D Kapoor, K S Channer, and T H Jones Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes Eur. J. Endocrinol., December 1, 2008; 159(6): 739 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Wang, E Nieschlag, R Swerdloff, H M Behre, W J Hellstrom, L J Gooren, J M Kaufman, J-J Legros, B Lunenfeld, A Morales, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations Eur. J. Endocrinol., November 1, 2008; 159(5): 507 - 514. [Full Text] [PDF]
|
|
|
|
|
|
A. A. Yassin and F. Saad Testosterone and Erectile Dysfunction J Androl, November 1, 2008; 29(6): 593 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rice, R. E. Brannigan, R. K. Campbell, S. Fine, L. Jack Jr, J. B. Nelson, and J. Regan-Klich Men's Health, Low Testosterone, and Diabetes: Individualized Treatment and a Multidisciplinary Approach The Diabetes Educator, November 1, 2008; 34(5_suppl): 97S - 112S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Farrell, A. Deshmukh, and A. A. Baghaie Low Testosterone and the Association With Type 2 Diabetes The Diabetes Educator, September 1, 2008; 34(5): 799 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Simon Testosterone deficiency--the male menopause? InnovAiT, September 1, 2008; 1(9): 625 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S A Paul Chubb, Z. Hyde, O. P Almeida, L. Flicker, P. E Norman, K. Jamrozik, G. J Hankey, and B. B Yeap Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men Study Eur. J. Endocrinol., June 1, 2008; 158(6): 785 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kapoor, K. S Channer, and T H. Jones Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes Diabetes and Vascular Disease Research, June 1, 2008; 5(2): 135 - 137. [Abstract] [PDF]
|
|
|
|
|
|
M. Grossmann, M. C. Thomas, S. Panagiotopoulos, K. Sharpe, R. J. MacIsaac, S. Clarke, J. D. Zajac, and G. Jerums Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1834 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Emmelot-Vonk, H. J. J. Verhaar, H. R. Nakhai Pour, A. Aleman, T. M. T. W. Lock, J. L. H. R. Bosch, D. E. Grobbee, and Y. T. van der Schouw Effect of Testosterone Supplementation on Functional Mobility, Cognition, and Other Parameters in Older Men: A Randomized Controlled Trial JAMA, January 2, 2008; 299(1): 39 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Allan, B. J. G. Strauss, H. G. Burger, E. A. Forbes, and R. I. McLachlan Testosterone Therapy Prevents Gain in Visceral Adipose Tissue and Loss of Skeletal Muscle in Nonobese Aging Men J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 139 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C Larsson and A. Wolk Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies Am. J. Clinical Nutrition, September 1, 2007; 86(3): 556 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Greenfield, S. J. Walters, R. E. Coleman, B. W. Hancock, R. Eastell, H. A. Davies, J. A. Snowden, L. Derogatis, S. M. Shalet, and R. J. M. Ross Prevalence and Consequences of Androgen Deficiency in Young Male Cancer Survivors in a Controlled Cross-Sectional Study J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3476 - 3482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B Yeap, O. P Almeida, Z. Hyde, P. E Norman, S A P. Chubb, K. Jamrozik, and L. Flicker In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study Eur. J. Endocrinol., May 1, 2007; 156(5): 585 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Kapoor, S Clarke, R Stanworth, K S Channer, and T H Jones The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes Eur. J. Endocrinol., May 1, 2007; 156(5): 595 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kapoor, H. Aldred, S. Clark, K. S. Channer, and T. H. Jones Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes: Correlations with bioavailable testosterone and visceral adiposity Diabetes Care, April 1, 2007; 30(4): 911 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bhasin, R. A. Parker, F. Sattler, R. Haubrich, B. Alston, T. Umbleja, C. M. Shikuma, and for the AIDS Clinical Trials Group Protocol A5079 Effects of Testosterone Supplementation on Whole Body and Regional Fat Mass and Distribution in Human Immunodeficiency Virus-Infected Men with Abdominal Obesity J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1049 - 1057. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
